BACKGROUND: Long-term comparative data of first-generation drug-eluting stents are scarce. We investigated clinical and angiographic outcomes of @entity3446 -eluting (SES) and @entity1311 -eluting stents (PES) at 5 years as part of the @entity3446 -Eluting Versus @entity1311 -Eluting Stents for Coronary Revascularization (SIRTAX) LATE study. METHODS AND RESULTS: A total of 1012 @entity1 were randomly assigned to SES or PES. Repeat angiography was completed in 444 of 1012 @entity1 (43.8%) at 5 years. Major adverse @entity299 occurred in 19.7% of SES- and 21.4% of PES-treated @entity1 (hazard ratio, 0.89; 95% confidence interval, 0.68 to 1.17; P=0.39) at 5 years. There were no differences between SES and PES in terms of @entity204 (5.8% versus 5.7%; P=0.35), @entity583 (6.6% versus 6.9%; P=0.51), and @entity75 revascularization (13.1% versus 15.1%; P=0.29). Between 1 and 5 years, the annual rate of @entity75 revascularization was 2.0% (95% confidence interval, 1.4% to 2.6%) for SES and 1.4% (95% confidence interval, 0.9% to 2.0%) for PES. Among @entity1 undergoing paired angiography at 8 months and 5 years, delayed @entity393 amounted to 0.37    0.73 mm for SES and 0.29    0.59 mm for PES (P=0.32). The overall rate of definite stent @entity715 was 4.6% for SES and 4.1% for PES (P=0.74), and very late definite stent @entity715 occurred at an annual rate of 0.65% (95% confidence interval, 0.40% to 0.90%). CONCLUSIONS: Long-term follow-up of first-generation drug-eluting stents shows no significant differences in clinical and angiographic outcomes between SES and PES. The continuous increase in late @entity393 in conjunction with the ongoing risk of very late stent @entity715 suggests that @entity455 remains incomplete up to 5 years after implantation of first-generation drug-eluting stents.

Five-year clinical and angiographic outcomes of a randomized comparison of @entity3446 -eluting and XXXX -eluting stents: results of the @entity3446 -Eluting Versus @entity1311 -Eluting Stents for Coronary Revascularization LATE trial.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular healing'] @entity75 :: ('MESH:D001927', 'Disease') :: ['target lesion'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel', 'Paclitaxel'] @entity3446 :: ('MESH:D020123', 'Chemical') :: ['sirolimus', 'Sirolimus'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac events'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity393 :: ('MESH:D034381', 'Disease') :: ['lumen loss'] @entity204 :: ('MESH:D003643', 'Disease') :: ['cardiac death'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis']
@entity1311 :: (MESH:D017239,Chemical) :: ['paclitaxel']
